A remote monitoring system detects indicators of worsening heart failure.
CardioMEMS HF System is a remote monitoring technology that detect changes in pulmonary artery pressure, which is an early indicator of worsening heart failure. The technology, from Abbott, alerts if a patient’s heart failure is worsening and gives clinicians actionable data to intervene before a patient feels symptoms.
The system, Phil Adamson, M.D., M.Sc., FACC, divisional vice president of Global Clinical Affairs, and chief medical officer of Abbott Laboratories, told Managed Healthcare Executive®, is a small micro electromechanical chip that’s placed in the pulmonary artery permanently and does not have a battery or lead. In fact, the U.S. Food and Drug Administration approved the device in 2014.
More than 20,000 patients have benefited so far from the system, Adamson said.
Although no studies have been done specifically on patients during the COVID-19 pandemic, Adamson said a real-world study was completed on 1,200 patients. Investigators found the system demonstrated around a 57% reduction in the need for hospitalization compared to historic controls. A follow-up will be conducted on 1,000 patients in a prospective randomized clinical trial in an enlarged population of whom the investigators think a hemodynamic-guided strategy would be effective.
“This is one of the largest device trials ever done and is certainly the largest hemodynamic-guided care trial ever done,” Adamson added.
CMS Coverage Decision of Pulmonary Embolectomy Criticized
November 19th 2021JAMA Internal Medicine editor and a UCSF colleague wrote in a New England Journ of Medicine opinion piece that the decision highlights the need to establish a new requirement that would make coverage decisions contingent on evidence of benefit for Medicare population.
Read More
FDA Updates: Genentech Withdraws Tecentriq Indication; New Approvals for Xarelto, Tibsovo
August 28th 2021Tecentriq loses indication, Xarelto is approved for reduce risks of cardiovascular events, Tibsovo is approved for rare cancer, Skytrofa is a new, once-weekly growth hormone, and supplemental application is filed Orencia graft-versus-host disease.
Read More
FDA Updates: Opdivo, Jardiance and Jemperli Get Nods for New Indications
August 21st 2021FDA approves Opdivo, Jardiance for new indication, Jemperli gets accelerated approval for solid tumors, and Lilly’s rapid-acting insulin, Lyumjev is approved for administration via an insulin pump.
Read More